Regarding effectiveness of atropine use in children and adolescents with progressive myopia (literature review)
https://doi.org/10.33791/2222-4408-2019-2-40-50
Abstract
The issue of myopia prevention or myopia control is becoming more and more relevant every year. The approaches to myopia pathogenesis and myopia control have changed fundamentally, stereotypes have been dispelled, hypotheses and numerous studies are becoming the basis of new scientific developments. However, the reality dictates the necessity to integrate the updated evidence based medicine data regarding myopia control into the clinical ophthalmological practice.
The main reason that concerns the professional community is a growing prevalence of progressive myopia among children and adolescents around the world.
The incidence of myopia among the adult population of European countries and theUnited Statesis estimated at 20-50%, whereas in Asian countries it amounts to 60-90%. In recent years, there was an increased interest towards the use of conservative methods of treatment in order to stabilize myopia, including the use of pharmacological agents. The publications from 1964 up until today were analyzed in the following review. They were focused on the results of studies that showed the effect of different concentrations of atropine on myopia progression in children and adolescents who had been observed during a maximum period of 5 years.
Conclusion. According to numerous studies, low-concentration atropine (0.01%) is an effective mean to slow the progression of myopia and stabilize refraction. In addition, long-term therapeutic use of this particular concentration of atropine is associated with the least frequent occurrence of negative side effects.
About the Authors
A. V. Myagkov
Academy of Medical Optics and Optometry
Russian Federation
Russian Federation
Med.Sc.D., Professor, Director
63B, bld. 4, Mikhalkovskaya St., Moscow, 125438, Russian Federation �дростки
T. Yu. Verzhanskaya
Centre of Orthokeratology, Myopia Control and Complex Vision Correction, “IMA Vision”
Russian Federation
Russian Federation
Ph.D., ophthalmologist, Head of Orthokeratology and Control of Myopia Department
2a, Leninsky prospect, Moscow, 119049, Russian Federation
E. V. Shibalko
Academy of Medical Optics and Optometry
Russian Federation
Russian Federation
M.D.
63B, bld. 4, Mikhalkovskaya St., Moscow, 125438, Russian Federation �дростки
References
1. Avetisov S.E., Fisenko V.P., Zhuravlev A.S, Avetisov K.S. Atropine use for the prevention of myopia progression.Vestn Oftalmol. 2018;134(4):84-90. (In Russ.) https://doi.org/10.17116 /oftalma2018;13404184
2. Morgan I., Rose K. How genetic is school myopia? Prog. Retin. Eye Res. 2005;24:1–38.
3. Wu P.-C., Chuang M.-N., Choi J., Chen H., Wu G., Ohno-Matsui K., Jonas J.B, Gemmy C., Cheung M. Update in myopia and treatment strategy of atropine use in myopia control. Eye (Lond). 2018. Jun 11. doi: 10.1038/s41433-018-0139-7.
4. Proskurina O.P., Markova E.Y., Brzheskij V.V., Efimova E.L., Efimova M.N., Chvatova N.N., Slychalova N.N., Egorova A.V. The prevalence of myopia in schoolchildren in some regions of Russia. Ophthalmology. 2018;15(3):348-353. (In Russ.) https://doi.org/10.18008/1816-5095-2018-3-348-353
5. Walline J.J., Lindsley K., Vedula S.S. et al. Interventions to slow progression of myopia in children. Cochrane Database Syst. Rev 2011:CD004916.
6. Huang J., Wen D., Wang Q. et al. Efficacy comparison of 16 interventions for myopia control in children: a network metaanalysis. Ophthalmology. 2016;123:697–708.
7. Khanal S., Turnbull P.R.K., Lee N., Phillips J.R. The effect of atropine on human global flash mfERG responses to retinal defocus. Invest Ophthalmol Vis Sci. 2019;60:218–225. https://doi.org/10.1167/iovs.18-24600
8. Kennedy R.H., Dyer J.A., Kennedy M.A., Parulkar S., Kurland L.T., Herman D.C. et al. Reducing the progression of myopia with atropine: a long term cohort study of Olmsted County students. Binocul Vis Strabismus Q. 2000;15(3 Suppl):281-304.
9. Bedrossian R.H. Review of the development and treatment of myopia – Cooper Eye Care. Ann Ophthalmol. 1989;21(5):180-182,187.
10. Bedrossian R.H. The effect of atropine on myopia. Ophthalmology. 1979;86(5):713-719.
11. Bedrossian R.H. The effect of atropine on myopia. Ann Ophthalmol. 1971;3(8):891-897.
12. Gimbel H.V. The control of myopia with atropine. Can J Ophthalmol. 1973;8(4):527-532.
13. Kelly T.S., Chatfield C., Tustin G. Clinical assessment of the arrest of myopia. Br J Ophthalmol. 1975;59(10):529-538.
14. Dyer J.A. Role of cyclopegics in progressive myopia. Ophthalmology. 1979;86(5):692-694.
15. Sampson W.G. Role of cycloplegia in the manage-ment of functional myopia. Ophthalmology. 1979;86(5):695-697.
16. Bedrossian R.H. The treatment of myopia with atropine and bifocals: a long-term prospective study. Ophthalmo-logy. 1985;92(5):716.
17. Gruber E. Treatment of myopia with atropine and bifocals. Ophthalmology. 1985;92(7):985.
18. Brodstein R.S., Brodstein D.E., Olson R.J., Hunt S.C., Williams R.R. The treatment of myopia with atropine and bifocals. A long-term prospective study. Ophthalmology. 1984;91(11):1373-1379.
19. Brenner R.L. Further observations on use of atropine in the treatment of myopia. Ann Ophthalmol. 1985;17(2):137-140.
20. Yen M.Y., Liu J.H., Kao S.C., Shiao C.H. Comparison of the effect of atropine and cyclopentolate on myopia. Ann Ophthalmol. 1989;21(5):180-182,187.
21. Shih Y.F., Chen C.H., Chou A.C., Ho T.C., Lin L.L., Hung P.T. Effects of different concentrations of atropine on controlling myopia in myopic children. J Ocul Pharmacol Ther. 1999;15(1):85-90.
22. Chiang M.F., Kouzis A., Pointer R.W., Repka M.X. Treatment of childhood myopia with atropine eyedrops and bifocal spectacles. Binocul Vis Strabismus Q. 2001;21(3):209-216.
23. Chua W.H., Balakrishnan V., Chan Y.H., Tong L., Ling Y., Quah B.L. et al. Atropine for the treatment of childhood myopia. Ophthalmology. 2006;113(12):2285-2291.
24. Chia A., Chua W.H., Cheung Y.B., Wong W.L., Lingham A., Fong A. et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0,5%, 0,1%, and 0,01% Doses (ATOM2). Ophthalmology. 2012;119; 347-354.
25. Chia A., Lu Q.S., Tan D. Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops. Ophthalmology. 2016;123(2):391-399. https://doi.org/10.1016/j.ophtha.2015.07.004
26. Bullimore M., Berntsen D. Low-dose atropine for myopia control: considering all the data. JAMA Ophthalmol. 2018;136:303.
27. Gong Q., Janowski M., Luo M. et al. Efficacy and adverse effects of atropine in childhoodmyopia: a meta-analysis. JAMA Ophthalmol. 2017;135(6):624-630.
28. Clark T.Y., Clark R.A. Atropine 0.01% eyedrops significantly reduce the progression of childhoodmyopia. J Ocul Pharmacol Ther. 2015;31(9):541-545.
29. Chia A., Chua W.H., Cheung Y.B. et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012;119(2):347-354.
30. Chua W.H., Balakrishnan V., Chan Y.H. et al. Atropine for the treatment of childhood myopia. Ophthalmology. 2006;113(12):2285-2291.
31. Chia A., Chua W.H., Wen L., Fong A, Goon Y.Y., Tan D. Atropine for the treatment of childhoodmyopia: changes after stopping atropine 0.01%, 0.1% and 0.5%. Am J Ophthalmol. 2014;157(2):451-457.e1.
32. Bergen M.A., Park H.N., Chakraborty R. et al. Altered refractive development in mice with reduced levels of retinal dopamine. Invest Ophthalmol Vis Sci. 2016; 57(10):4412-4419.
33. Schwahn H.N., Kaymak H., Schaeffel F. Effects of atropine on refractive development, dopamine release, and slow retinal potentials in the chick. Vis Neurosci. 2000;17(2):165-176.
34. Cavallotti C., Pescosolido N., Artico M., Feher J. Localization of dopamine receptors in the rabbit cornea. Cornea. 1999;18(6):721-728.
35. Grub M., Mielke J., Rohrbach M., Schlote T. Dopamine receptors of the corneal epithelium and endothelium [in German]. Klin Monbl Augenheilkd. 2012;229(8):822-825.
36. Yam J.C., Jiang Y., Tang S.M. et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study: a ran-domized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmol. 2019;126:113-124.
Review
For citations:
Myagkov A.V., Verzhanskaya T.Yu., Shibalko E.V. Regarding effectiveness of atropine use in children and adolescents with progressive myopia (literature review). The EYE GLAZ. 2019;21(2 (126)):40-50. (In Russ.) https://doi.org/10.33791/2222-4408-2019-2-40-50
Views:
680
Email this article 